12/8/14 - 'Tis the season for snow and less sunshine. Supplementing with vitamin D during these cold months becomes even more important. For the appropriate dose, check with your neurologist or IMSMP patients can schedule a consult with Dr. Bates, our naturopathic doctor.


by Dr. James W. Stark

11/25/14 - Plegridy was recently approved by the FDA for the treatment of relapsing forms of MS and is now available for use. Plegridy is another interferon, specifically pegylated interferon B-1a. It is similar to other interferons currently available but is administered every two weeks by a subcutaneous injection. Side effects were similar to other interferons, however, because it is administered every two weeks, side effects were seen less frequently than...


11/17/14 - The FDA has approved Lemtrada (Alemtuzumab) for the treatment of RRMS. Lemtrada has been available to treat MS in Europe and Canada and has also been used in the United States to treat leukemia. Lemtrada will likely be reserved for patients with very aggressive forms of relapsing MS, as there are a number of safety considerations with this medication.


11/17/14 - Dr. Armistead Williams has been named by New York Super Doctors® as one of the rising star doctors in New York for 2014. The number of doctors receiving this honor is limited to approximately five percent of the region’s active physicians.  

11/11/14 - Read the review and more updates on reasearch in the Tisch MS Research laboratory at:

http://www.tischms.org/news/tisch-msrcny-phase-1-stem-cell-clinical-tria...’s-review-news


10/27/14 - The following is a brief review of some future MS therapies presented by our MS Specialists during the Neurology Roundtable Discussion at the 17th Annual Tisch MS Patient Symposium: Siponimod is an oral medication in development that is in the same class of drugs as Fingolimod, but may have fewer associated adverse events. Ocrelizumab is very similar to Rituximab, but will be much easier to obtain approval from insurance companies when it is FDA-approved for MS. Daclizumab is a...


10/24/14 - A fatal case of progressive multifocal leukoencephalopathy has been reported in a multiple sclerosis patient taking Tecfidera (dimethyl fumarate). Although details of this case are still being disseminated, we believe the patient had not been previously treated with Tysabri or immunosuppressants, making this the first case of PML attributable to Tecfidera. Apparently the patient did have prolonged (>3 years) of lymphopenia (or a very low lymphocyte count), which is a known...


Thank you to all who attended the 17th Annual Tisch MS Research Patient Symposium.  In response to your requests, a review of the material presented will be posted on this website and appear in the next issue of our newsletter, Healing MS.


Dr. Duson Stefoski from Rush University in Chicago spoke at Grand Rounds this morning.  Dr. Stefoski is the Director of the Rush Multiple Sclerosis Center and has extensive experience in the diagnosis and management of Progressive Multifocal Leukoencephalopathy (PML). PML is the infection associated with prolonged Tysabri administration, for which there are no approved treatments.  Dr.


Pages

Subscribe to IMSMP Weekly Update